Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 10 - 06 symbols : Sny save search
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
Published: 2022-10-06 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: -2.52%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -0.79%
H: 1.14%
C: -1.28%
partnership research state mrna
Autoimmune Hemolytic Anemia Therapeutics Market to Record a CAGR of 9.1%, Majority of Market Growth to Originate from North America - Technavio
Published: 2022-10-06 (Crawled : 23:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
|
| O: -3.32%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: -2.52%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 0.07%
H: 0.92%
C: 0.27%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: -1.8%
BAX | News | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: -0.64%
H: 0.45%
C: -0.48%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.55%
H: 0.79%
C: -0.65%
ARGX | $358.65 -2.06% -2.11% 240K
|
Health Technology
|
| O: -3.19%
H: 0.91%
C: -0.99%
america anemia therapeutics growth market
Global Nanomedicine Market to Reach $433.9 Billion by 2027 at a 13.46% CAGR
Published: 2022-10-06 (Crawled : 20:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -4.81%
H: 0.0%
C: -2.52%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -4.56%
H: 0.29%
C: 0.29%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.16%
H: 0.09%
C: -0.67%
GE | $152.94 -1.75% 0.0% 6M
|
Electronic Technology
|
| O: -0.92%
H: 0.25%
C: -1.6%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: 0.05%
H: 2.53%
C: -0.69%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
global market
Lilly's Mounjaro is on the Fast Track Toward Potential Obesity Approval
Published: 2022-10-06 (Crawled : 16:00) - biospace.com/
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: -0.8%
H: 0.9%
C: -1.38%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
obesity approval potential
Anticipating FDA "Yes", Provention Inks Co-Promotion Deal with Sanofi for T1D Drug
Published: 2022-10-06 (Crawled : 16:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
fda drug deal sanofi
Anticipating FDA "Yes", Provention Inks Co-Promotion Deal with Sanofi for T1D...
Published: 2022-10-06 (Crawled : 15:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
fda deal sanofi
Anticoagulants Market is expected to generate a revenue of USD 56.16 Billion by 2028, Globally, at 10.20% CAGR: Verified Market Research®
Published: 2022-10-06 (Crawled : 14:20) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.53%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.82%
H: 0.03%
C: -1.53%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -1.25%
H: 0.53%
C: -0.1%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.92%
H: 0.06%
C: -0.78%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
research expected market
Framework Solutions Launches Medical Affairs Division with Appointment of Key Executive
Published: 2022-10-06 (Crawled : 13:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
solutions
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Published: 2022-10-06 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 24.09%
H: 0.0%
C: 0.0%
teplizumab diabetes potential sanofi
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Published: 2022-10-06 (Crawled : 12:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 24.09%
H: 0.0%
C: 0.0%
diabetes agreement therapy sanofi
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.